Your Smartphone Transformed into a Mobile Lab

Your Smartphone Transformed into a Mobile Lab

April 30, 2015

From University of Tasmania - Research to Reality:

A new University of Tasmania collaboration is aiming to bring the complexities of in-house laboratory testing to the fingertips of those in the field.

In a move promised to revolutionise the way complex samples are carried out, a $5.2 million Australian Research Council Training Centre for Portable Analytical Separation Technologies (ASTech) was established late last year.

The University has partnered with Australian company Trajan Scientific and Medical and the Federal Government to explore new technologies which ultimately bring the laboratory to the sample.

"What if you could carry out a full suite of tests on a pin-prick droplet of blood … What if you could carry out tests on your smartphone?"

Read the full article at UTAS website.




Also in News

Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst

September 07, 2020

Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.

Read More

European patent for Trajan’s hemaPEN
European patent for Trajan’s hemaPEN

July 13, 2020

Trajan Scientific and Medical is proud to advise that the European Patent Office will be granting a patent for hemaPEN® as a liquid collection device in Belgium, France, Germany, Ireland, Luxembourg, Monaco, Switzerland, Liechtenstein and the United Kingdom. Extensions are being sought across the remainder of Europe.

Read More

US FDA listing of Trajan’s hemaPEN blood microsampling device
US FDA listing of Trajan’s hemaPEN blood microsampling device

July 02, 2020

Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.

Read More